Institute of Pharmacy, Ernst Moritz Arndt University, Greifswald, Germany.
J Pharm Pharmacol. 2012 Jul;64(7):944-68. doi: 10.1111/j.2042-7158.2012.01477.x. Epub 2012 Feb 21.
The in-vivo performance of oral modified-release dosage forms is determined by the interplay of various physiological- and dosage-form-derived parameters. Thus it is often a challenge to predict the in-vivo drug-release behaviour from modified-release dosage forms based solely on in-vitro release rates.
For a long time the most common procedure to obtain in-vitro/in-vivo correlations for modified-release formulations was to apply test conditions typically used for quality control on a retrospective basis. Such so-called 'compendial approaches' are typically not biorelevant with respect to volumes, composition and physicochemical properties of the test media and also do not take into consideration the mechanical and hydrodynamic forces that may influence dosage-form behaviour during passage through the gastrointestinal tract.
This review provides an overview of physiological conditions relevant to in-vivo drug release and of dissolution models which, based on current scientific findings on human gastrointestinal physiology, have been developed to enable a better prediction of the in-vivo performance of oral MR dosage forms.
口服缓控释剂型的体内性能取决于各种生理和剂型衍生参数的相互作用。因此,仅基于体外释放速率来预测缓控释剂型的体内药物释放行为通常具有挑战性。
长期以来,获得缓控释制剂体内/体外相关性的最常见方法是回顾性地应用通常用于质量控制的测试条件。这种所谓的“药典方法”通常与测试介质的体积、组成和物理化学性质没有生物相关性,也没有考虑可能影响胃肠道通过过程中剂型行为的机械和流体动力。
本文综述了与体内药物释放相关的生理条件以及溶解模型,这些模型基于当前对人体胃肠道生理学的科学发现,旨在更好地预测口服 MR 剂型的体内性能。